

08-31-00

A

08/30/00

JC917 U.S. PTO

Please type a plus sign (+) inside this box →

Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))</small>	Attorney Docket No. <b>P00154US/13238/00016</b>
	First Inventor or Application Identifier <b>Filutowicz, M.</b>
	Title <b>Anti-Microbial Biotherapeutic Agents</b>
	Express Mail Label No. <b>EL582440230US</b>

JC841 U.S. PTO  
09/651290  
08/30/00

<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents.</small>	<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
--	---

- \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
- Specification [Total Pages **25**]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
- Drawing(s) (35 U.S.C. 113) [Total Sheets **2**]
- Oath or Declaration [Total Pages ]
  - Newly executed (original or copy)
  - Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)
    - DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

- Microfiche Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - Computer Readable Copy
  - Paper Copy (identical to computer copy)
  - Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS	
7. <input type="checkbox"/>	Assignment Papers (cover sheet & document(s))
8. <input type="checkbox"/>	37 C.F.R. §3.73(b) Statement of Attorney (when there is an assignee) <input type="checkbox"/> Power of Attorney
9. <input type="checkbox"/>	English Translation Document (if applicable)
10. <input type="checkbox"/>	Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations
11. <input type="checkbox"/>	Preliminary Amendment
12. <input checked="" type="checkbox"/>	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
13. <input type="checkbox"/>	* Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)
14. <input type="checkbox"/>	Certified Copy of Priority Document(s) (if foreign priority is claimed)
15. <input type="checkbox"/>	Other: .....

**NOTE FOR ITEMS 1 & 13:** IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

16. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment.

Continuation  Divisional  Continuation-in-part (CIP) of prior application No: \_\_\_\_\_ / \_\_\_\_\_

Prior application information: Examiner \_\_\_\_\_ Group / Art Unit: \_\_\_\_\_

**For CONTINUATION or DIVISIONAL APPS only:** The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. **CORRESPONDENCE ADDRESS**

Customer Number or Bar Code Label  Correspondence address below

(Insert Customer No. or Attach bar code label here)

Name	Janet E. Reed				
Address	Saul, Ewing, Remick & Saul, LLP Centre Square West 1500 Market St. 38th Floor				
City	Philadelphia	State	PA	Zip Code	19102
Country	USA	Telephone	215-972-8386	Fax	215-972-2292

Name (Print/Type)	Janet E. Reed	Registration No. (Attorney/Agent)	36,252
Signature	<i>Janet E. Reed</i>	Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

EL582440230US

+



consequence of antibiotic uses. Over the last several decades, the increasingly frequent usage of antibiotics has acted in concert with spontaneous mutations arising in the bacterial gene pool to produce antibiotic resistance in certain strains. This gene pool is continually utilized by previously sensitive strains capable of accessing it by various means including the transfer of extrachromosomal elements (plasmids) by conjugation. As a result, single- and multi-drug resistance mutations are commonly found in a large variety of bacterial plasmids.

Presently there is no known method by which to avoid the selection of antibiotic resistant bacterial mutants that arise as a result of the many standard applications of antibiotics in the modern world. Accordingly, a need exists to develop alternative strategies of antibacterial treatment.

Interest in the use of bacteriophages to treat infectious bacterial diseases developed early in the twentieth century, and has undergone a resurgence in recent years. For instance, bacteriophages have been shown effective in the treatment of certain pathogenic *E. coli* species in laboratory and farm animals, and have been proposed as a viable alternative to the use of antibiotics (Smith & Huggins, *J. Gen. Microbiol.* 128: 307-318, 1981; Smith & Huggins, *J. Gen. Microbiol.* 129: 2659-2675, 1983; Smith et al., *J. Gen. Microbiol.* 133: 1111-1126, 1986; Kuvda et al., *Appl. Env. Microbiol.* 65: 3767-3773, 1999). However, the use of bacteriophages as antimicrobial agents has certain limitations. First, the relationship between a phage and its host bacterial cell is typically very specific, such that a broad host-range phage agent generally is unavailable. Second, the specificity of interaction usually arises at the point of the recognition and binding of phage to the host cell. This often occurs through the expression of surface receptors on the host cell to which a phage specifically binds. Inasmuch as such receptors are usually encoded by a single gene, mutations in the host bacterial cell to alter the surface receptor, thereby escaping detection by the phage, can occur with a frequency equivalent to or higher than, the mutation rate to acquire antibiotic resistance. As a result, if phage were utilized as commonly as antibiotics, resistance of pathogenic bacteria to phages could become as common a problem as antibiotic resistance.

00000"0627550

Another approach to controlling pathogenic bacteria has been proposed, which relies on using molecular biological techniques to prevent the expression of antibiotic resistance genes in pathogenic bacteria (U.S. Patent No. 5,976,864 to Altman et al.). In this method, a nucleic acid construct encoding an “external guide sequence” specific for the targeted antibiotic resistance gene is introduced into the pathogenic bacterial cells. The sequence is expressed, hybridizes with messenger RNA (mRNA) encoding the antibiotic resistance gene product, and renders such mRNA sensitive to cleavage by the enzyme RNase P. Such a system also has limited utility, since it is targeted to specific antibiotic resistance genes. While the system may be effective in overcoming resistance based on expression of those specific genes, continued use of the antibiotics places selective pressure on the bacteria to mutate other genes and develop resistance to the antibiotic by another mechanism.

It is clear from the foregoing discussion that current alternatives to antibiotic use are limited and suffer many of the same drawbacks as antibiotic use itself. Thus, a need exists for a method of controlling pathogenic bacteria that is flexible in range and that cannot be overcome by the bacteria by a single small number of mutations.

### **SUMMARY OF THE INVENTION**

The present invention provides novel antibacterial agents that are efficiently transferred to pathogenic bacteria, which have a flexible range, and to which the target bacteria have difficulty developing resistance. These antibacterial agents offer an effective alternative to the use of conventional antibiotics.

According to one aspect of the invention, an antibacterial agent is provided which comprises a non-pathogenic donor bacterial cell harboring at least one transmissible plasmid having the following features: (a) an origin of replication for synthesizing the plasmid’s DNA in a bacterial cell, wherein initiation of replication at the origin of replication is negatively controlled by a plasmid replication repressor; (b) an origin of transfer to provide the initiation site for conjugative transfer of the transmissible plasmid from the donor cell to at least one recipient cell; and (c) at least one selectable

marker gene. The donor bacterial cell further comprises one or more conjugative transfer genes conferring upon the donor cell the ability to conjugatively transfer the transmissible plasmid to the recipient cell. The donor cell also produces the plasmid replication repressor. The recipient cell is a pathogenic bacterium that does not produce the plasmid replication repressor.

According to another aspect of the invention, a different antibacterial agent is provided which comprises a non-pathogenic donor bacterial cell harboring at least one transmissible plasmid having these following features: (a) an origin of replication for synthesizing the plasmid's DNA in a bacterial cell; (b) an origin of transfer to provide the start site for conjugative transfer of the transmissible plasmid from the donor cell to at least one recipient cell; and (c) at least one killer gene that, upon expression in a bacterial cell, produces a product that kills the cell. The donor cell again comprises one or more transfer genes conferring upon the donor cell the ability to conjugatively transfer the transmissible plasmid to the recipient cell, and is modified so as to be unaffected by the product of the killer gene. The recipient cell is a pathogenic bacterium that has not been modified so as to be unaffected by the product of the killer gene.

The present invention also provides methods of treating a patient for a pathogenic bacterial infection which comprises administering to the patient one of the aforementioned antibacterial agents. The mode of administration is selected to ensure that the donor cells of the antibacterial agent come into conjugative proximity to the pathogenic bacterial cells, such that the transmissible plasmids of the donor cells are conjugatively transferred from the donors to the pathogenic cells. Following conjugation and dependent upon the nature of the plasmid, it either undergoes unchecked replication or the at least one killer gene is expressed to produce a gene product that is detrimental or lethal to the pathogenic bacterial cells.

The present invention also provides pharmaceutical preparations for treating a patient for a bacterial infection. These preparations comprise one of the aforementioned antibacterial agents, formulated for a pre-determined route of administration to the patient.

Other features and advantages of the present invention will be understood by reference to the drawings, detailed description and examples that follow.

**BRIEF DESCRIPTION OF THE DRAWINGS**

5                   **Fig. 1.** Schematic diagram showing process of killing pathogenic bacteria by conjugative transfer of plasmids that engage in runaway replication in the recipient cells.

**Fig. 2A.** Schematic diagram of a non-self-transmissible, runaway replication plasmid system using a helper plasmid and a transmissible runaway replication plasmid.

**Fig. 2B.** Schematic diagram of a self-transmissible, runaway replication plasmid system.

**DETAILED DESCRIPTION OF THE INVENTION**

15                   The present invention provides novel antibacterial strategies that utilize the highly efficient bacterial conjugation system to transfer a “killer” plasmid from a donor cell that is engineered to be immune to the killer plasmid, to a target bacterial cell that is not.

                    In one aspect of the invention, the “killer plasmid” is one that undergoes runaway replication in the recipient cells, ultimately killing the cells. The basic principles underlying the mechanism by which runaway plasmid replication kills cells are outlined below.

                    Plasmids are dispensable DNA molecules that are stably maintained in bacterial populations. Plasmids replicate extra-chromosomally inside the bacterium and can transfer their DNA from one cell to another by a variety of mechanisms. DNA sequences controlling extra-chromosomal replication (*ori*) and transfer (*tra*) are distinct from one another; i.e., a replication sequence cannot control plasmid transfer, and vice-versa. Replication and transfer are both complex molecular processes that require plasmid- and host-encoded functions.

00000 "00000000



Naturally occurring plasmids are present within host cells at a characteristic concentration (referred to herein as a particular plasmid's "copy number"). Of great significance to the present invention is the fact that plasmid copy number is negatively controlled. Thus, mutations that destroy the elements of the negative control cause an over-replication phenotype that manifests itself by an increase in the plasmid's copy number ("copy-up" phenotype). In extreme cases of copy-up mutations, plasmid replication is completely unchecked due to the loss of copy control mechanisms. This is referred to as "runaway plasmid replication" or simply "runaway replication."

Runaway plasmid replication is lethal for the host cell. This is because, although the plasmid encodes the replication (Rep) protein that controls its copy number, all other replication proteins are encoded by chromosomal genes. These chromosomally encoded proteins assemble into a complex called a replisome. A typical bacterial cell possesses a small, fixed number of replisomes. Because both the chromosome and the plasmids require the same replisomes for DNA synthesis, an excess of plasmids acts like a trap to occupy all of the cell's replisomes. This results in the inability of the cell's chromosome to replicate, ultimately leading to the death of the host cell.

The use of runaway replication plasmids as a means to kill recipient cells has a number of advantages over conventional antibiotic methodologies. One significant advantage is that, since the entire host replication machinery is targeted, multiple mutations would be required to avoid death by elevating the expression or activity of the replisome sub-assemblies. For instance, mutations in ten genes would be required just to increase the amount or activity of DNA polymerase III holoenzyme (composed of ten different subunits), and this polymerase is just one of the replisome's sub-assemblies. Thus, there is little or no chance of a bacterium acquiring resistance to being killed by over-replicating plasmids. In contrast, conventional antibiotics typically inhibit only a single enzymatic activity that is essential for the cell's survival. A single-target strategy unavoidably leads to the quick acquisition of resistance to such drugs, caused by the relatively high spontaneous mutation frequency for one gene ( $10^{-6}$  to  $10^{-8}$ ).

Because runaway replication mutations are lethal to the host cell, donor

2025 RELEASE UNDER E.O. 14176



cells that maintain such plasmids must be engineered so that replication control is restored. This is accomplished by providing the wild-type Rep protein to the host cell, either on another plasmid or by integration into the bacterial chromosome using standard homologous recombination techniques.

5            Thus, the runaway replication plasmid, antibacterial strategy of the invention comprises the following basic components:

(1) a plasmid that, alone or with the assistance of a helper plasmid, comprises the genes necessary to effect conjugative transfer of the plasmid from a donor cell to a recipient cell; the replication of the plasmid is negatively controlled by a gene  
10 that can be de-activated (via mutation) so as to release the negative control on plasmid replication (referred to as a “runaway replication plasmid”);

(2) optionally, a helper plasmid with the requisite conjugative transfer genes; and

(3) a donor cell for maintaining the runaway replication plasmid in  
15 a replication-suppressed state, so as not to be killed by the plasmid.

A number of conjugative plasmids have been well characterized, and can serve as subjects for mutagenesis to create runaway mutants, which may be used in embodiments of the present invention. Such mutants contain all components needed for conjugative self-transfer from donor to recipient cells but are defective in their replicative  
20 repressor (Rep) function. Examples of such mutants, both broad-range and narrow-range, are known in the art (Haugan et al., *Plasmid* 33: 27-39, 1995; Molin et al., *J. Bacteriol.* 143: 1046-1048, 1980; Toukdarian & Helinski, *Gene* 223: 205-211, 1998). A particularly preferred plasmid of this type is a mutant of plasmid R6K, as described in detail in Examples 1 and 2. Other examples include, but are not limited to, RK2, pCU1, p15A,  
25 pIP501, pAM $\beta$ 1 and pCRG1600.

As an alternative to the use of mutants, it may sometimes be preferable to use various components of conjugative plasmids whose features are well understood, to create plasmids having all necessary features. Features required on runaway replication plasmids or helper plasmids include (1) an origin of replication (*oriV* herein), the

sequence from which replication of the plasmid originates and the sequence that is negatively regulated by a Rep protein; (2) an origin of transfer (*oriT* herein), the sequence from which the conjugal plasmid transfer originates; (3) the transfer (*tra*) genes required in *trans* to effect conjugation; and (4) a screenable marker gene that would function in a donor but not in the recipient cells. The donor cell containing the runaway replication plasmid is engineered to contain a functional repressor (Rep) of replication at *oriV*, thereby controlling replication of the runaway replication plasmid while it is still in the donor.

Two basic systems are contemplated: a non-self-transmissible plasmid system and a self-transmissible plasmid system. These are shown schematically in Figs. 2A and 2B.

In the non-self-transmissible system (Fig. 2A), the runaway replication plasmid contains an *oriT*, an *oriV* and a screenable marker gene. The helper plasmid contains the additional *tra* genes, along with its own origin of replication and a selective marker. Thus, the helper plasmid enables conjugative transfer of the runaway replication plasmid, but is itself confined to the donor cell due to its lack of an *oriT*. Since the runaway replication plasmid lacks the necessary *tra* genes to convert the recipient cell into a donor cell, the cycle of conjugation ends with the original recipient cell. It cannot transfer its runaway replication plasmid to a second recipient before it dies.

In the self-transmissible system (Fig. 2B), the runaway replication plasmid contains an *oriT*, an *oriV* and a screenable marker gene. It also contains the additional *tra* genes needed for conjugative transfer. Thus, unlike the non-self-transmissible plasmid described above, once this plasmid has been transmitted from the original donor to a first recipient, it is capable of transmitting itself again to subsequent recipients before the first recipient cell is killed by runaway replication. A plasmid of this type has the capability of much faster dissemination among recipient cells than the non-self-transmissible type, resulting in faster and more widespread killing of those cells.

In either the self-transmissible or the self-non-transmissible system, the donor cells must contain a gene encoding a functional Rep protein that represses plasmid

5 replication initiated at *oriV*. The Rep-encoding gene is typically integrated into the donor genomic DNA. Plasmid DNA comprising the Rep-encoding gene is introduced into bacterial cells by any commonly known technique (e.g., transformation). The Rep-encoding gene can be integrated into the host genome by a site-specific recombination, according to standard methods (Li-Ch Huang, E. Wood and M. Cox; J. Bacteriol. 179: 6076-6083, 1997).

10 A number of bacterial *oriV*'s and the Rep proteins that negatively control them have been characterized. Each of these is contemplated for use in the present invention. Examples of suitable *oriV*/Rep systems for use in the invention include, but are not limited to: RK2, R6K, rts 1, p15A, RSF1010, F and P1.

15 The selection of *oriV* will confer on the system its range of potential recipients for runaway replicating plasmids. In most instances it may be preferable to target a specific pathogen as recipient of the runaway replication plasmid. Such instances include, but are not limited to using the conjugative runaway plasmids for combating Enterobacteria, Enterococci, Staphylococci and non-sporulating Gram-positive pathogens such as *Nocardia* and *Mycobacterium sp.* Examples of selective host range plasmids from which such *oriV*'s may be obtained include, but are not limited to, P1 and F.

20 In instances where it is desirable to affect a wide variety of pathogenic recipients, a broad range *oriV* is employed. Examples of broad range ("promiscuous") plasmids from which *oriV*'s may be obtained include, but are not limited to: R6K, RK2, p15A and RSF1010.

25 As used herein, the term "range" (or "host range") refers generally to parameters of both the number and diversity of different bacterial species in which a particular plasmid (natural or recombinant) can replicate. Of these two parameters, one skilled in the art would consider diversity of organisms as generally more defining of host range. For instance, if a plasmid replicates in many species of one group, e.g., Enterobacteriaceae, it may be considered to be of narrow host range. By comparison, if a plasmid is reported to replicate in only a few species, but those species are from phylogenetically diverse groups, that plasmid may be considered of broad host range. As

discussed above, both types of plasmids (or components thereof) will find utility in the present invention.

Conjugative transfer (*tra*) genes also have been characterized in many conjugative bacterial plasmids. The interchangeability between the gene modules  
5 conferring the ranges of hosts susceptible for conjugal transfer and vegetative replication include Gram-positive and Gram-negative species. Examples of characterized *tra* genes that are suitable for use in the present invention are the *tra* genes from: (1) F (Firth, N., Ippen-Ihler, K. and Skurray, R.A. 1996, Structure and function of F factor and mechanism of conjugation. In: *Escherichia coli* and *Salmonella*, Neidhard et al., eds., ASM Press,  
10 Washington D.C.); (2) R6K (Nunez, B., Avila, P. and de la Cruz, 1997, Genes involved in conjugative DNA processing. Mol. Microbiol. 24: 1157-1168); and (3) Ti (Ferrand, S.K., Hwang, I. and Cook, D.M. 1996, The *tra* region of Nopaline type Ti plasmid is a chimera with elements related to the transfer systems of RSF1010, RP4 and F. J. Bacteriol. 178: 4233-4247).

15 According to another aspect of the invention, the bacterial conjugation system is again utilized, this time to efficiently deliver a variety of “killer genes” to target bacterial cells. The delivery of various killer genes to bacterial cells occurs in nature, upon infection of bacteria with bacteriophages. Bacteriophages utilize a number of different mechanisms to maintain their own replication cycles, generally resulting in lysis  
20 of the host bacterial cells. Indeed, bacteriophages have been proposed and used as alternatives to antibiotics, as discussed above in the Background of the Invention. One serious drawback to the use of bacteriophages for this purpose is that they are often extremely host-specific, binding only to cell surfaces possessing specific receptors. As a result, bacteria quickly develop resistance mutations in the receptor, thereby escaping  
25 recognition by the phage. The present invention circumvents that drawback by placing the killer genes (from a phage or other source) on a conjugative plasmid. The conjugative plasmid containing the killer gene, like the conjugative runaway replication plasmids described above, is thereafter efficiently distributed to recipient cells.

Bacteriophage kill host cells by a variety of mechanisms, many of which

03627550

are encoded by a discrete set of genes in the phage genome. For instance, bacteriophage MS2 contains a gene encoding a bacterial lysis protein (Coleman, J., Inouye, M. and Atkins, J. 1983. Bacteriophage MS2 lysis protein does not require coat protein to mediate cell lysis. J. Bacteriol. 153: 1098-1100). Phage T4D contains genes encoding proteins that degrade cytosine-containing DNA in bacterial host cells (Kutter, E. and Wilberg, J. 1968. Degradation of cytosine-containing bacterial and bacteriophage DNA after infection of *E. coli* B with bacteriophage T4D wild type and with mutants defective in genes 46, 47 and 56. J. Mol. Biol. 38: 395-411). Other T4 phage encode gene products that interfere with transcription of cytosine-containing DNA (Drivdahl, R. and Kutter, E. 1990. Inhibition of transcription of cytosine-containing DNA *in vitro* by alc gene product of bacteriophage T4. J. Bacteriol. 172: 2716-2727). Yet other T4 gene products are responsible for the disruption of the bacterial nucleoid (Bouet, J., Woszczuk, J., Repoila, F., Francois, V., Jouarn, J. and Krisch, H. 1994. Direct PCR sequencing of the *ndd* gene of bacteriophage T4: identification of the gene product responsible for the disruption of the bacterial nucleoid. Gene 141: 9-16). Genes such as these can be inserted into a conjugative plasmid such as those described above, for efficient distribution to target recipient cells.

In addition, other types of killer genes may be utilized similarly. These include naturally-occurring or synthetic genes. A nonlimiting example of a naturally-occurring gene that is suitable for use in the invention is the *hok* gene product described by Gerdes et al. (Gerdes, K., Bech, F., Jorgensen S., Loebner-Olsen, A., Rasmussen, P., Atlung, T., Boe, L., Karlstrom, O., Molin S., and von Meyenburg K. 1986. Mechanism of postsegregational killing by the *hok* gene product of the *parB* system of plasmid R1 and its homology with *rel F* gene product of the *E. coli relB* operon. EMBO J. 5: 2023-2029). Examples of man-made nucleic acid molecules that may be used in this aspect of the invention include: (1) sequences encoding non-hemolytic  $\beta$ -amino acid oligomers, which are a new class of based on inhibitors of Sigma-Core RNA polymerase interaction; (2) sequences encoding peptides with bactericidal activity and endotoxin neutralizing activity for Gram-negative bacteria as described in U.S. Patent 5,830,860; (3)

sequences encoding RNA molecules with binding affinity to critical bacterial cellular targets (e.g., Chen, H., Gold, L. 1994. Selection of high affinity RNA ligands to reverse transcriptase: Inhibition of cDNA synthesis and Rnase H activity. *Biochemistry* 33: 8746-8756); and (4) oligonucleotides generated by the *SELEX* method for the *in vitro* evolution of nucleic acid molecules with highly specific binding to target molecules as described in U.S. Pat. No. 5,475,096 and U.S. Pat. No. 5,270,163.

In these systems, death of the donor plasmid must be considered. It can be prevented by employing a synthetic promoter-operator system whose expression is prevented by the repressor made only in the donor cells.

Regardless of the type of killer plasmid that is utilized, the plasmid must contain a screenable marker gene. In traditional molecular biological manipulations of recombinant bacteria, the screenable marker gene is an antibiotic resistance gene. Since the present invention is designed to avoid further spread of antibiotic resistance, an alternative screenable marker system is preferred for use in the present invention.

Accordingly, though antibiotic resistance markers can be used, preferred screenable markers are nutritional markers, i.e., any auxotrophic strain (e.g., Trp<sup>-</sup>, Leu<sup>-</sup>, Pro<sup>-</sup>) containing a plasmid that carries a complementing gene (e.g., trp<sup>+</sup>, leu<sup>+</sup>, pro<sup>+</sup>).

The donor bacterial strain for any of the above-described killer plasmids can be any one of thousands of non-pathogenic bacteria associated with the body of warm-blooded animals, including humans. Preferably, non-pathogenic bacteria that colonize the non-sterile parts of the body (e.g., skin, digestive tract, urogenital region, mouth, nasal passages, throat and upper airway, ears and eyes) are utilized as donor cells, and the methodology of the invention is used to combat bacterial infections of these parts of the body. In another embodiment, safe donors of these plasmids are developed for combating systemic infection. Examples of particularly preferred donor bacterial species include, but are not limited to: (1) non-pathogenic strains of *Escherichia coli* (*E. coli* F18 and *E. coli* strain Nissle 1917), (2) various species of *Lactobacillus* (such as *L. casei*, *L. plantarum*, *L. paracasei*, *L. acidophilus*, *L. fermentum*, *L. zeae* and *L. gasseri*), (3) other nonpathogenic or probiotic skin-or GI colonizing bacteria such as *Lactococcus*,



clinical efficacy of a particular donor strain).

For instance, to deliver the bacteria to the gastrointestinal tract or to the nasal passages, the preferred mode of administration is by oral ingestion or nasal aerosol, or by feeding (alone or incorporated into the subject's feed or food). In this regard, it should be noted that probiotic bacteria, such as *Lactobacillus acidophilus*, are sold as gel capsules containing a lyophilized mixture of bacterial cells and a solid support such as mannitol. When the gel capsule is ingested with liquid, the lyophilized cells are re-hydrated and become viable, colonogenic bacteria. Thus, in a similar fashion, donor bacterial cells of the present invention can be supplied as a powdered, lyophilized preparation in a gel capsule, or in bulk for sprinkling into food or beverages. The re-hydrated, viable bacterial cells will then populate and/or colonize sites throughout the upper and lower gastrointestinal system, and thereafter come into contact with the target pathogenic bacteria.

For topical applications, the bacteria may be formulated as an ointment or cream to be spread on the affected skin surface. Ointment or cream formulations are also suitable for rectal or vaginal delivery, along with other standard formulations, such as suppositories. The appropriate formulations for topical, vaginal or rectal administration are well known to medicinal chemists.

The present invention will be of particular utility for topical or mucosal administrations to treat a variety of bacterial infections or bacterially related undesirable conditions. Some representative examples of these uses include treatment of (1) conjunctivitis, caused by *Haemophilus sp.*, and corneal ulcers, caused by *Pseudomonas aeruginosa*; (2) otitis externa, caused by *Pseudomonas aeruginosa*; (3) chronic sinusitis, caused by many Gram-positive cocci and Gram-negative rods; (4) cystic fibrosis, associated with *Pseudomonas aeruginosa*; (5) Enteritis, caused by *Helicobacter pylori* (ulcers), *Escherichia coli*, *Salmonella typhimurium*, *Campylobacter* and *Shigella sp.*; (6) open wounds, both surgical and non-surgical, as a prophylactic measure for many species; (7) burns to eliminate *Pseudomonas aeruginosa* or other Gram-negative pathogens; (8) acne, caused by *Propionibacter acnes*; (9) nose and skin infections caused by methicillin



resistant *Staphylococcus aureus* (MSRA); (10) body odor caused mainly by Gram-positive anaerobic bacteria (i.e., use in deodorants); (11) bacterial vaginosis associated with *Gardnerella vaginalis* and other anaerobes; and (12) gingivitis and/or tooth decay caused by various organisms.

5                   Pharmaceutical preparations comprising the donor bacteria are formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to a physically discrete unit of the pharmaceutical preparation appropriate for the patient undergoing treatment. Each dosage should contain a quantity of the donor bacteria calculated to produce the desired antibacterial effect in association  
10 with the selected pharmaceutical carrier. Procedures for determining the appropriate dosage unit are well known to those skilled in the art.

                  Dosage units may be proportionately increased or decreased based on the weight of the patient. Appropriate concentrations for achieving eradication of pathogenic bacteria in a target cell population or tissue may be determined by dosage concentration  
15 curve calculations, as known in the art.

                  Other uses for the donor bacteria of the invention are also contemplated. These include agricultural and horticultural applications, such as: (1) use on meat or other foods to eliminate pathogenic bacteria; (2) use in animal feed (chickens, cattle) to reduce bio-burden or to reduce or eliminate particular pathogenic organisms (e.g., *Salmonella*);  
20 (3) use on fish to prevent "fishy odor" caused by *Proteus* and other organisms; and (4) use on cut flowers to prevent wilting.

                  The following examples are set forth to describe the invention in greater detail. They are intended to illustrate, not to limit, the invention. Unless otherwise specified, general cloning, microbiological, biochemical and molecular biological  
25 procedures such as those set forth in Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory (1989) ("Sambrook et al.") or Ausubel et al. (eds) Current Protocols in Molecular Biology, John Wiley & Sons (2000) ("Ausubel et al.") are used.

#### EXAMPLE 1

**Preparation of Runaway Replication  
Plasmid from Plasmid R6K**

5 Plasmid R6K is an *Escherichia coli* conjugative plasmid. Replication of R6K derivatives containing its *oriV* called  $\gamma$  *ori* requires a Rep protein,  $\pi$ , which is encoded by the plasmid's *pir* gene.  $\pi$  protein is bifunctional in replication; it acts as an activator of replication at low cellular levels and an inhibitor of replication at elevated levels. For a review of R6K replication and its control by  $\pi$  protein, see Filutowicz & Rakowski (1998) *Gene* 223, 195-204.

10 Using site-directed mutagenesis, the inventor has obtained the following three types of mutations within the *pir* gene:

(1) double amino acid substitution: pro106leu, phe107ser (numbering of residues according to Stalker et al. (1982) *J. Mol. Biol.* 161: 33-43).

(2) deletion of codons 106 and 107; and

15 (3) deletion of codons 105, 106 and 107.

The mutated *pir* genes were combined with the  $\gamma$  *ori* in two locations. In one location, the mutant gene was contained on a plasmid different from the plasmid containing the  $\gamma$  *ori*, thus providing  $\pi$  protein in *trans*. In another location, the mutant *pir* gene was contained on the same plasmid with the  $\gamma$  *ori*, thus providing its function in *cis*.

20

**EXAMPLE 2  
Bacterial Cells Transformed with Plasmids  
Containing Mutated *pir* and  $\gamma$  *ori* in *cis* are Killed**

25 *Escherichia coli* cells were transformed with either (1) the plasmids containing a mutated *pir* gene and the  $\gamma$  *ori* in *trans*; or (2) a plasmid containing a mutated *pir* gene and the  $\gamma$  *ori* in *cis*.

In transformed cells containing the mutant *pir* and the  $\gamma$  *ori* in *trans*, the copy number of the  $\gamma$  *ori* plasmid was increased 20- to 25-fold in comparison to wild-type *pir* controls. Cells transformed with the mutant *pir* and the  $\gamma$  *ori* in *cis* were killed  
30 by the runaway replication of  $\gamma$  *ori*. The occurrence of the runaway phenotype when

mutant *pir* is in *cis* to the *ori* but not in *trans* is believed to be caused by the enhanced effect of the origin activation and translation of nascent  $\pi$  protein occurring next to each other.

- 5 The present invention is not limited to the embodiments described and exemplified above, but is capable of variation and modification without departure from the scope of the appended claims.

00000000000000000000

**We claim:**

1. An antibacterial agent, which comprises a non-pathogenic donor bacterial cell harboring at least one transmissible plasmid comprising:

5 a) an origin of replication for synthesizing the plasmid in a bacterial cell, wherein initiation of replication at the origin is negatively controlled by a plasmid replication repressor;

10 b) an origin of transfer from which conjugative transfer of the transmissible plasmid initiates from the donor cell to at least one recipient cell; and, optionally,

c) at least one screenable marker gene;

15 wherein the donor cell further comprises one or more transfer genes conferring upon the donor cell the ability to conjugatively transfer the transmissible plasmid to the recipient cell, and wherein the donor cell produces the plasmid replication repressor, and further wherein the at least one recipient cell is a pathogenic bacterium that does not produce the plasmid replication repressor.

20 2. The antibacterial agent of claim 1, wherein the transfer genes are contained on a helper plasmid within the donor cell, such that the transmissible plasmid is transmissible from the donor cell to a recipient cell, but is not further self-transmissible from the recipient cell to another recipient cell.

25 3. The antibacterial agent of claim 1, wherein the transfer genes are contained on the transmissible plasmid, such that the transmissible plasmid is self-transmissible from the donor cell to a recipient cell, and further from the recipient cell to another recipient cell.

4. The antibacterial agent of claim 1, wherein the transmissible plasmid comprises a derivative of a naturally-occurring transmissible plasmid containing a gene

03E20 062F550

encoding the replication repressor that has been mutated to produce a non-functional replication repressor.

5                5. The antibacterial agent of claim 4, wherein the naturally-occurring transmissible plasmid is selected from the group consisting of RK2, R6K, pCU1, p15A, pIP501, pAMβ1 and pCRG1600.

10              6. The antibacterial agent of claim 5, wherein the naturally-occurring plasmid is R6K and the mutation comprises a mutation in the R6K *pir* gene such that its encoded  $\pi$  protein comprises an at least one amino acid deletion or substitution at amino acids 105, 106 or 107.

15              7. The antibacterial agent of claim 1, wherein the donor cell is a non-pathogenic strain of bacteria selected from the group consisting of *Escherichia coli*, *Lactobacillus spp.*, *Lactococcus*, *Bifidobacteria*, *Eubacteria*, and bacterial minicells.

20              8. The antibacterial agent of claim 1, wherein the recipient cell is a pathogenic strain of bacterium selected from the group consisting of *Campylobacter spp.*, *Enterobacter spp.*, *Enterococcus spp.*, *Escherichia coli*, *Gardnerella vaginalis*, *Haemophilus spp.*, *Helicobacter pylorii*, *Mycobacterium tuberculosis*, *Propionobacter acnes*, *Pseudomonas aeruginosa* and other *Pseudomonas spp.*, *Salmonella typhimurium*, *Shigella spp.* and *Staphylococcus spp.*

25              9. The antibacterial agent of claim 1, wherein the origin of replication is derived from a plasmid selected from the group consisting of R6K, RK2, rts1, p15A and RSF1010.

                10. The antibacterial agent of claim 1, wherein the origin of replication is selected from the group consisting of F and P1.

11. The antibacterial agent of claim 1, wherein the screenable marker gene confers a nutritional selection advantage on cells containing the transmissible plasmid.

5 12. The antibacterial agent of claim 1, wherein the transfer genes are derived from a plasmid selected from the group consisting of F, R6K and Ti.

10 13. A method of treating a patient for a pathogenic bacterial infection, which comprises administering to the patient the antibacterial agent of claim 1 in a manner such that the donor cells of the antibacterial agent come into conjugative proximity to the pathogenic bacterial cells, such that the transmissible plasmids of the donor cells are transferred from the donor cells to the pathogenic bacterial cells, whereupon the transmissible plasmids commence unchecked replication, thereby killing the pathogenic bacterial cells.

15 14. A pharmaceutical preparation for treating a patient for a bacterial infection, comprising the antibacterial agent of claim 1 formulated for a pre-determined route of administration to the patient.

20 15. The pharmaceutical preparation of claim 14, wherein the pre-determined route of administration is selected from the group consisting of: topical, oral, nasal, pulmonary, ophthalmic, aural, rectal, urogenital, subcutaneous, intraperitoneal and intravenous.

25 16. An antibacterial agent, which comprises a non-pathogenic donor bacterial cell harboring at least one transmissible plasmid comprising:

a) an origin of replication for synthesizing the plasmid in a bacterial cell;

b) an origin of transfer from which conjugative transfer of the transmissible plasmid initiates from the donor cell to at least one recipient cell;

c) at least one killer gene that, upon expression in a bacterial cell, produces a product that kills the cell; and, optionally,

d) at least one screenable marker gene;

5 wherein the donor cell further comprises one or more transfer genes conferring upon the donor cell the ability to conjugatively transfer the transmissible plasmid to the recipient cell, and wherein the donor cell is modified so as to be unaffected by the product of the killer gene, and further wherein the at least one recipient cell is a pathogenic bacterium that has not been modified so as to be unaffected by the product of the killer gene.

10

17. The antibacterial agent of claim 16, wherein the transfer genes are contained on a helper plasmid within the donor cell, such that the transmissible plasmid is transmissible from the donor cell to a recipient cell, but is not further self-transmissible from the recipient cell to another recipient cell.

15

18. The antibacterial agent of claim 16, wherein the transfer genes are contained on the transmissible plasmid, such that the transmissible plasmid is self-transmissible from the donor cell to a recipient cell, and further from the recipient cell to another recipient cell.

20

19. The antibacterial agent of claim 16, wherein the killer gene kills the cells by being expressed and thereby producing a gene product that is detrimental or lethal to bacterial cells, and the donor cells have been modified so as to repress the expression of the killer gene, thereby avoiding production of the detrimental or lethal gene product.

25

20. The antibacterial agent of claim 16, wherein the killer gene is obtained from a bacteriophage.

21. The antibacterial agent of claim 20, wherein the bacteriophage is selected from the group consisting of T-series phages, P1, p22 and  $\lambda$ .

5 22. The antibacterial agent of claim 16, wherein the donor cell is a non-pathogenic strain of bacteria selected from the group consisting of *Escherichia coli*, *Lactobacillus spp.*, *Lactococcus*, *Bifidobacteria*, *Eubacteria*, and bacterial minicells.

10 23. The antibacterial agent of claim 16, wherein the recipient cell is a pathogenic strain of bacterium selected from the group *Campylobacter spp.*, *Enterobacter spp.*, *Enterococcus spp.*, *Escherichia coli*, *Gardnerella vaginalis*, *Haemophilus spp.*, *Helicobacter pylorii*, *Mycobacterium tuberculosis*, *Propionobacter acnes*, *Pseudomonas aeruginosa* and other *Pseudomonas spp.*, *Salmonella typhimurium*, *Shigella spp.* and *Staphylococcus spp.*

15 24. The antibacterial agent of claim 16, wherein the origin of replication is derived from a plasmid selected from the group consisting of R6K, RK2, rts1, p15A and RSF1010.

20 25. The antibacterial agent of claim 16, wherein the origin of replication is selected from the group consisting of F and P1.

25 26. The antibacterial agent of claim 16, wherein the screenable marker gene confers a nutritional selection advantage on cells containing the transmissible plasmid.

27. The antibacterial agent of claim 16, wherein the transfer genes are derived from a plasmid selected from the group consisting of F, R6K and Ti.

28. A method of treating a patient for a pathogenic bacterial infection,



which comprises administering to the patient the antibacterial agent of claim 16 in a manner such that the donor cells of the antibacterial agent come into conjugative proximity to the pathogenic bacterial cells, such that the transmissible plasmids of the donor cells are transferred from the donor cells to the pathogenic bacterial cells,  
5 whereupon the at least one killer gene is expressed, thereby producing the product that kills the pathogenic bacterial cells.

29. A pharmaceutical preparation for treating a patient for a bacterial infection, comprising the antibacterial agent of claim 16 formulated for a pre-determined  
10 route of administration to the patient.

30. The pharmaceutical preparation of claim 29, wherein the pre-determined route of administration is selected from the group consisting of: topical, oral, nasal, pulmonary, ophthalmic, aural, rectal, urogenital, subcutaneous, intraperitoneal and  
15 intravenous.

030000057560

**ABSTRACT**

Novel antimicrobial agents that can serve as replacements to conventional  
5 pharmaceutical antibiotics are disclosed. The antimicrobial agents comprise  
conjugatively transmissible plasmids that kill targeted pathogenic bacteria, but are not  
harmful to donor bacteria. Two types of lethal transmissible plasmids are disclosed. One  
type kills recipient bacteria by unchecked (“runaway”) replication in the recipient cells  
and is prevented from occurring in donor cells. Another type kills recipient bacteria by  
10 expressing a gene that produces a product detrimental or lethal to recipient bacterial cells,  
that gene being prevented from expression in donor cells.

033E22 0627550




Fig. 1

300000 "3027550




Fig. 2A




Fig. 2B